Divi's Laboratories Jumps 7.5% as Profit Surges 64%

Divi's Laboratories jumped 7.5% in India's special Diwali Muhurat session on Sunday, November 8, 2026, after the pharmaceutical company reported a 64% year-on-year rise in quarterly profit to Rs 1,127 crore. The move made Divi's the standout large-cap gainer in a flat session and lifted the pharma index 1.7%, even as the Nifty 50 slipped 0.18% to 24,986.40.

What happened

Divi's Laboratories reported its results for the quarter ended September 30, 2026, on Saturday, November 7. Consolidated net profit rose to Rs 1,127 crore from Rs 689 crore a year earlier, a rise of 63.6%. Revenue from operations rose 35.4% to Rs 3,676 crore from Rs 2,715 crore, and total income rose 32% to Rs 3,770 crore from Rs 2,860 crore.

Sunday was the first chance for investors to trade on the numbers. India held a one-hour Muhurat session from 2:20 p.m. to 3:30 p.m. IST to mark Diwali and the start of Samvat 2083. In that short window, Divi's rose 7.5%, according to Reuters, leading the pharma sector while the wider market paused after a seven-session rally of more than 10%.

Key facts at a glance

• Net profit: Rs 1,127 crore, up 63.6% from Rs 689 crore a year earlier
• Revenue from operations: Rs 3,676 crore, up 35.4% from Rs 2,715 crore
• Total income: Rs 3,770 crore, up about 32% from Rs 2,860 crore
• Profit before tax: Rs 1,505 crore, up 65% from Rs 912 crore
• EBITDA: Rs 1,566 crore, up 76% from Rs 888 crore, with margin at about 42.6%
• Earnings per share: Rs 42.49, up from Rs 25.97 a year earlier
• Sunday move: Shares up 7.5% in the Muhurat session; pharma index up 1.7%

Why it's blowing up

Three things came together. First, the profit growth was not just a revenue story — margins expanded sharply. EBITDA rose faster than sales, which points to operating leverage in Divi's core business of manufacturing active pharmaceutical ingredients, intermediates and nutraceutical ingredients.

Second, the result landed in a market already looking for earnings to justify a rapid rally. Foreign portfolio investors bought about Rs 45,961 crore of Indian shares over five sessions last week, and benchmarks had risen in seven straight sessions before Sunday. A clean, large earnings beat from a Nifty constituent gave that momentum a fresh name to focus on.

Third, the timing helped. Results came on a Saturday, so there was no intraday reaction to fade. The Sunday session was short, ceremonial and thinly traded compared with a normal day, which can amplify moves in individual stocks.

The half-year picture

For the first half of FY27, consolidated total income was Rs 6,907 crore, compared with Rs 5,389 crore a year earlier. Half-year profit after tax reached Rs 2,029 crore. On the earnings call, the company said exports continue to make up about 90% of standalone sales revenue, and its global nutraceutical business recorded Rs 571 crore in the first half, compared with Rs 492 crore a year earlier.

Not every line moved in the same direction. First-half operating cash inflow was Rs 384 crore, down from Rs 1,645 crore a year earlier, and the quarterly forex gain fell to Rs 24 crore from Rs 63 crore. Those details are part of the filing and help explain why investors will look beyond the headline profit number when normal trading resumes.

What this means for the wider market

Divi's move stood out because the rest of Sunday's session was quiet. The Sensex closed down 0.04% at 80,999.40, small-caps rose about 1% and mid-caps rose 0.1%, and metals gained 0.4% with Tata Steel up about 2.1%. In that setting, a 7.5% rise in a large pharma stock was the clearest earnings reaction of the day, and it showed that September-quarter results — not just foreign flows — are now driving individual names.

This report describes what happened and the figures the company published. It is not a recommendation to buy, sell or hold any security.

What's next

Normal trading resumes on Monday, November 9, when investors will see whether Divi's holds the Muhurat gain in a full session with regular volumes. Attention will also turn to whether the margin expansion seen in this quarter can be sustained, and to management commentary on demand for custom synthesis and generic APIs. Broader Indian markets will be watching foreign flows after last week's surge and the October U.S. inflation data due Tuesday, November 10.

Sources

Reuters — Indian shares consolidate in Diwali session after seven-day rally, November 8, 2026
The Hindu BusinessLine — Divi's Lab net profit surges 63% to Rs 1,127 crore in Q2, November 7, 2026
Multibagg — Divi's Laboratories Q2 profit rises 64% to Rs 1,127 crore

FAQ

Why did Divi's Laboratories shares jump on Sunday?

Divi's rose 7.5% in the November 8 Muhurat session after reporting a 64% rise in quarterly profit, the first trading reaction to results published on November 7.

What were Divi's Laboratories Q2 FY27 results?

Net profit was Rs 1,127 crore, up 63.6% year on year, on revenue from operations of Rs 3,676 crore, up 35.4%, and total income of Rs 3,770 crore.

What does Divi's Laboratories make?

Divi's manufactures active pharmaceutical ingredients, intermediates and nutraceutical ingredients, with exports making up about 90% of standalone sales revenue.

When does normal trading resume in India?

Regular NSE and BSE trading resumes on Monday, November 9, 2026, after Sunday's one-hour Diwali Muhurat session.